心力衰竭患者肾上腺髓质中段肽及钠尿肽的测定及其临床意义

Determination of serum MR-proADM and BNP in heart failure patients and their clinical significance

目的探讨心力衰竭(CHF)患者血清肾上腺髓质中段肽及钠尿肽的浓度及其临床意义。方法应用双抗体夹心法测定心力衰竭患者35例(CHF组)及正常健康体检者31例(对照组)血清中的肾上腺髓质中段肽(MRproADM)及钠尿肽(BNP)水平,并进行对照分析。结果 CHF组血清肾上腺髓质中段肽及钠尿肽水平显著高于对照组(P<0.05),Ⅱ、Ⅲ、Ⅳ级心力衰竭组间有显著差异(P<0.05),治疗前后各组MR-proADM、BNP水平亦有显著差异(P<0.01)。结论血清MR-proADM与BNP一起可作为CHF诊断、分级及治疗效果评价的有效指标。

Objective To study the changes of serum midregional pro-adrenomedullin （MR-proAMD） levels and B- type natriuretic peptide （BNP） levels in chronic heart failure （CHF） . Methods Serum MR-proAMD and BNP levels in 35 patients with CHF and 31 healthy individuals as control were determined by Sandwich-ELISA. Results Serum MR- proAMD and BNP levels were increased significantly in CHF patients compared with those in the control group （P〈 0.05） ,and in Ⅱ , Ⅲ, IV grade patients the difference were significant（P〈0. 05） , and after treatment the both markers levels decreased than before（P〈0. 01）. Conclusion Both serum MR-proAMD and BNP test may be useful markers for diagnosis,grading and follow up in CHF patients.